Retroperitoneal mass presentations of B-immunoblastic sarcoma

Area of Science:

• Oncology
• Pathology
• Hematology

Background:

• B-immunoblastic sarcoma (B-IBS) is an aggressive non-Hodgkin's lymphoma (NHL) characterized by large B-cells.
• This study focuses on B-IBS presenting as a retroperitoneal mass, analyzing its clinicopathologic features.

Purpose of the Study:

• To report on the clinicopathologic features of B-immunoblastic sarcoma presenting as a retroperitoneal mass.
• To evaluate treatment outcomes and prognostic factors in patients with this specific NHL subtype.

Main Methods:

• Clinicopathologic analysis of nine patients with B-immunoblastic sarcoma (B-IBS).
• Review of patient demographics, clinical presentation, disease stage, B symptoms, and treatment modalities (chemotherapy, radiation therapy, surgery).
• Correlation of initial blood lymphocyte count with patient survival.

Main Results:

• Patients presented with bulky retroperitoneal masses, abdominal pain, and B symptoms; mean age was 60.5 years.
• Chemotherapy (CHOP-B or ACOMLA) provided palliation in 5/9 patients (mean survival 12.3 months).
• Untreated or radiation-treated patients had poor survival; pleuropulmonary involvement was common in disseminated disease. Initial lymphocyte count correlated significantly with survival (r=0.84).

Conclusions:

• B-immunoblastic sarcoma (B-IBS) presenting as a retroperitoneal mass is a distinct, aggressive clinicopathologic entity.
• Chemotherapy offers palliation, but outcomes remain poor for many patients.
• Surgical debulking prior to chemotherapy may improve remission rates, as suggested by one durable complete remission.